1xbet 모바일 Pharmaceutical Co., Ltd.

1xbet 모바일 Pharmaceutical Co., Ltd. (1xbet 모바일) and Novartis Pharma K.K. (Novartis Pharma) on February 29, 2020, executed a co-promotion agreement in Japan for Novartis Pharma's angiotensin receptor neprilysin inhibitor (ARNI) LCZ696 (generic name: sacubitril valsartan sodium hydrate) currently being developed by Novartis Pharma as a planned treatment for chronic heart failure.

Under the terms of this agreement, Novartis Pharma and 1xbet 모바일 will jointly undertake the promotion of LCZ696 to healthcare practitioners in Japan. 1xbet 모바일 will pay an upfront payment of JPY 10 billion and additional milestones to Novartis Pharma. Novartis Pharma will pay to 1xbet 모바일 a promotion fee according to the sales of the product. No further financial terms were disclosed.

LCZ696 is a new type of drug that reduces cardiac load 1xbet 모바일 chronic heart failure by activat1xbet 모바일g a protective neurohormonal mechanism (natriuretic peptide system) while suppress1xbet 모바일g the harmful effects of overactivity of the ren1xbet 모바일-angiotens1xbet 모바일-aldosterone system (RAAS).^1,2Novartis Pharma is currently apply1xbet 모바일g for approval of the drug 1xbet 모바일 Japan with a planned 1xbet 모바일dication for chronic heart failure.

Novartis Pharma President and Representative Director Kazunari Tsunaba said, "1xbet 모바일 Pharmaceutical has extensive institutional knowledge in the area of heart failure, so I am delighted that we have been able to form this contract together. Through this partnership, we can better meet the medical needs of patients struggling with chronic heart failure in Japan."

1xbet 모바일 President and Representative Director Tatsuo Higuchi said, "We are honored that our work in our key focus area of renal and cardiovascular disease has been recognized by Novartis, which has one of the leading drug portfolios in the world. I look forward to seeing this collaboration provide chronic heart failure patients in Japan with a new treatment option."

References

1. EMA. Entresto (sacubitril/valsartan). Summary of product characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_1xbet 모바일formation/human/004062/WC500197536.pdf. Accessed July 2019.

2. Langenickel T, Dole W. Angiotens1xbet 모바일 receptor-neprilys1xbet 모바일 1xbet 모바일hibition with LCZ696: a novel approach for the treatment of heart failure. Drug Discov Today. 2012;9(4):e131-139. doi: 10.1016/j.ddstr.2013.11.002.